Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Completes $12M Public Offering

NEW YORK (GenomeWeb News) – CombiMatrix today said it has closed its public offering of 12,000 units of Series D convertible preferred stock and warrants, raising $12 million in gross proceeds.

The units were priced at $1,000 each, and consisted of one share of Series D convertible preferred stock — which can be converted into 485.4369 shares of common stock at a conversion price of $2.06 per share — and one warrant to purchase 485.4369 shares of common stock at an exercise price of $3.12 per share.

The array-based molecular diagnostic company disclosed its offering in September and priced its offering earlier this week.

Net proceeds from the offering are anticipated to be about $10.8 million, CombiMatrix said. Ladenburg Thalmann was the underwriter on the offering,

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.